Nucleai Partners with the University of Glasgow to Pioneer AI-Powered Multimodal Precision Medicine for Colorectal Cancer

Great to see Nucleai continue shaping the future of precision medicine.

In a newly announced collaboration with the University of Glasgow, Nucleai is pioneering the use of AI-powered spatial biology to improve early detection and prevention of colorectal cancer. The partnership will integrate multimodal data, including tissue, molecular, and clinical sources, to identify predictive biomarkers and personalize patient surveillance.

The effort builds on data from the INCISE study, one of the world’s largest and most comprehensive cohorts of precancerous colorectal polyps. By analyzing tissue architecture, cell interactions, and molecular signaling, the collaboration aims to uncover how early biological changes influence cancer progression and how these insights can be translated into deployable diagnostics.

This partnership marks a major step toward bringing multimodal spatial biology into real-world care. Today, most clinical diagnostics rely on limited data types. Nucleai’s platform uniquely unifies spatial proteomics, tissue imaging (mIF, IHC, H&E), and clinical history within an automated AI workflow, enabling biomarker discovery and validation at scale and with unprecedented biological depth.

“This collaboration is a significant step toward realizing the promise of multimodal spatial precision medicine,” said Avi Veidman, CEO of Nucleai. “By combining Glasgow’s leadership in spatial biology with our AI-powered platform, we’re moving from discovery to deployable diagnosticsת translating complex biological data into actionable clinical insights.”

Leaders at the University of Glasgow echoed the impact of the partnership, noting its potential to accelerate spatial biomarker discovery and drive personalized surveillance strategies for colorectal cancer.

This work also highlights Nucleai’s broader vision: building the operating system for next-generation precision medicine. By expanding its multimodal platform beyond drug development into diagnostics, Nucleai aims to connect academia, clinical institutions, and life science partners in a global precision medicine network.

Congratulations to Avi Veidman and the entire Nucleai team for leading the charge in translating discovery into clinical impact.

Read the full announcement here.